To hear about similar clinical trials, please enter your email below
Trial Title:
Molecular Analysis and Treatment Options of SCLC
NCT ID:
NCT05945745
Condition:
Small-cell Lung Cancer
Small Cell Lung Cancer, Combined Type
Small Cell Lung Carcinoma
Small Cell Lung Cancer Extensive Stage
Small Cell Lung Cancer Limited Stage
Conditions: Official terms:
Lung Neoplasms
Small Cell Lung Carcinoma
Immunomodulating Agents
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Drug
Intervention name:
Chemotherapy
Description:
different treatments based on the molecular analysis
Other name:
immunotherapy
Other name:
targeted therapy
Summary:
Small cell lung cancer (SCLC) is an aggressive disease that is characterized by rapid
growth and the early development of metastases. Patients typically respond to initial
chemotherapy but quickly experience relapse, resulting in a poor long-term outcome.
Therapeutic innovations that substantially improve survival have historically been
limited, and reliable, predictive biomarkers are lacking.
Ongoing research has advanced the understanding of molecular categories and the
immunologic microenvironment of SCLC, which in turn has helped improve disease
classification and staging. Considering the role of molecular alterations has not yet
fully to be defined in the treatment of SCLC, there is an urgent recognition that
molecular alterations in the SCLC are important to predict response and survival for
novel therapies and ongoing clinical trials. Advances in research have revealed critical
information regarding biologic characteristics of the disease, which may lead to the
identification of vulnerabilities and the development of new therapies. Further research
focused on identifying biomarkers and evaluating innovative therapies will be paramount
to improving treatment outcomes for patients with SCLC.
In summary, identification of (genetic) biomarkers in SCLC is increasingly essential to
perform molecular diagnostics and individualized treatments. This project aims to create
a registry of patients with SCCL to further the characterization of molecular alterations
and develop (novel) treatments based on the detection.
Criteria for eligibility:
Study pop:
Participants with SCLC are with the standard treatment and/or are enrolled in the
clinical trials.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Histologically proven diagnosis of SCLC
- 18 years of age or older
- Ability to understand and the willingness to sign a written informed consent
document
Exclusion Criteria:
- Histologically proven diagnosis of non-SCLC
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Locations:
Facility:
Name:
Shanghai Chest Hospital
Address:
City:
Shanghai
Country:
China
Status:
Recruiting
Contact:
Last name:
Xiaomin Niu
Phone:
021-22200000
Email:
ar_tey@hotmail.com
Start date:
January 1, 2016
Completion date:
December 31, 2028
Lead sponsor:
Agency:
Shanghai Chest Hospital
Agency class:
Other
Source:
Shanghai Chest Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05945745
